Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.

You may also be interested in...

NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA

Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.

Roche’s Actemra Beats Methotrexate In Rheumatoid Arthritis

Interleukin-6 inhibitor is first biologic to show superiority in reducing signs and symptoms.

Roche’s Actemra Gets Advisory Committee Review

FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts